Autolus Therapeutics PLC (AUTL)

NASDAQ: AUTL · IEX Real-Time Price · USD
2.57
+0.07 (2.80%)
Jun 24, 2022 4:00 PM EDT - Market closed
2.80%
Market Cap 233.66M
Revenue (ttm) 2.23M
Net Income (ttm) -145.89M
Shares Out 90.92M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,884
Open 2.58
Previous Close 2.50
Day's Range 2.49 - 2.63
52-Week Range 1.96 - 7.90
Beta 1.59
Analysts Buy
Price Target 12.41 (+382.9%)
Earnings Date Aug 4, 2022

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; ... [Read more...]

Industry Biotechnology
IPO Date Jun 22, 2018
Employees 324
Stock Exchange NASDAQ
Ticker Symbol AUTL
Full Company Profile

Financial Performance

In 2021, AUTL's revenue was $2.33 million, an increase of 35.86% compared to the previous year's $1.72 million. Losses were -$142.10 million, 0.00% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is 12.41, which is an increase of 382.88% from the latest price.

Price Target
$12.41
(382.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma - AUTO1/22 demonstrates encouraging and durable responses in children ineligible for comme...

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice o...

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, ...

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that ...

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel...

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

- Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST -

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therap...

Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products Developing cell programming capabilities to improve our pipeline of precise, controlled...

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the...

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic...

LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced tha...

Autolus Therapeutics to Participate in Conferences During April 2022

- Wells Fargo Annual Biotech Forum on April 12 and 13 -

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

- Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT - - Conference call to be held on March 10, 2022 at 8:30 am ET/1:30 pm GMT -

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

Autolus Therapeutics PLC Sponsored ADR (AUTL) Loses 22.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the C...

The heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement ...

Autolus Therapeutics announces retirement of chief financial officer and succession plan

- Andrew J. Oakley to retire in March 2022

Autolus Therapeutics announces 2022 priorities

- obe-cel has the potential to transform outcomes for adult ALL patients

Autolus Therapeutics to Present at Conferences During January 2022

LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & E...

Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that...

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

Tetracycline and minocycline controllable CAR T cell system to manage toxicities Tetracycline and minocycline controllable CAR T cell system to manage toxicities

Market Highlights: Stocks react to earnings release, Blackstone invests $250 billion in Autolus, Elon Musk to sell 10...

Roblox Corp (NYSE: RBLX) shares jumped 30% after hours on Monday after the company posted robust fiscal Q3 results thanks to demand surge with the easing of COVID-19 restrictions. As a result, the video...

Other symbols: BXTSLA

Why Autolus Therapeutics Stock Jumped 25% Today

A private equity firm is taking a $100 million stake in the biotech.

AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher Today

Autolus Therapeutics (AUTL) stock is surging higher in trading Monday following news of a major investment in the company. The post AUTL Stock: Why Little-Known Autolus Therapeutics Is Rocketing Higher ...

Blackstone triggers a 30% increase in Autolus Therapeutics shares

Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of it...

Other symbols: BX